SCHEMBL2804955

SCHEMBL2804955

COc1ccc(Nc2ccc(N(C)C(=O)C3(NC(=O)c4cncnc4)CC3)nc2)c(C(F)(F)F)c1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.36
PTK2 Q05397 2/20 0.35
DHODH Q02127 2/20 0.34
PROKR1 Q8TCW9 2/20 0.34
EPHX2 P34913 3/20 0.33
EGFR P00533 2/20 0.33
BTK Q06187 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
ABL1 P00519 2/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
MAPK10 P53779 1/20 0.33
BDKRB1 P46663 1/20 0.33
GRM5 P41594 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL185280 0.92 PIK3CA (0.36) PIK3CAPTK2DHODHPROKR1EGFR
SCHEMBL2805105 0.90 BDKRB1 (0.34) PTK2EGFRHDAC3HDAC1HDAC2
SCHEMBL2806524 0.90 BRAF (0.38) DHODHEGFRABL1MAPK10BDKRB1
SCHEMBL2809231 0.90 DHODH (0.35) PTK2DHODHEGFRGPBAR1ABL1
SCHEMBL2809360 0.89 BDKRB1 (0.33) PTK2EGFRHDAC3HDAC1HDAC2
SCHEMBL2808764 0.89 CNR2 (0.38) PROKR1CNR2MAPK10BDKRB1
SCHEMBL2804889 0.87 MAPK9 (0.36) PTK2DHODHHDAC3HDAC1HDAC2
SCHEMBL2805743 0.85 BDKRB1 (0.34) PTK2EGFRHDAC3HDAC1HDAC2
SCHEMBL185613 0.84 SMO (0.33) GPBAR1CNR2MAPK10GRM5
SCHEMBL2804952 0.83 BDKRB1 (0.43) PIK3CAPTK2EPHX2BTKBDKRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131075-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 PIK3CA 3430/4885PTK2 3921/4885DHODH 2925/4885
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 PIK3CA 3430/4885PTK2 3921/4885DHODH 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.